To understand whether the p53-regulated mdm2 gene expression was altered by the Epstein-Barr virus (EBV) in nasopharyngeal carcinoma (NPC), the NPC-TW01 cell line was infected by EBV through IgA receptor-mediated endocytosis. The mdm2 gene was expressed only in a small fraction of the NPC cell population and could be enhanced in the EBV-infected (EBV þ ) cells. In the animals bearing EBV þ and EBV À NPC xenografts, the MDM2 þ cells only appeared in clusters in both EBV þ and EBV À tumors with stronger expression in EBV þ cells. Cotransfection of pmdm2-Luc plus pSV40-p53 plus pCMV-LMP1 in the NPC-TW06 line that had p53 heterozygous point mutation showed stronger mdm2 promoter activity than cells cotransfected with pmdm2-Luc plus pSV40-p53, but no mdm2 promoter activity was seen in cells cotransfected with pmdm2-Luc plus pCMV-LMP1. Only the EBV-LMP1 but not the EBV-LMP2A gene could enhance p53 to upregulated mdm2 expression. Tumor cells in NPC biopsy specimens revealed similar mdm2 expression as in the animal model. It is concluded that although EBV can indirectly enhance mdm2 gene expression in tumor cells that express this gene, it cannot turn on or directly regulate mdm2 expression in cells that do not express this gene. In other words, EBV plays a role as an enhancer in NPC tumorigenesis.
1
Although Epstein-Barr virus (EBV) has been closely associated with NPC, 2, 3 hereditary and environmental factors, such as salted fish, Chinese herbs and long-term exposure to sulfuric acid vapor, have also been suspected to be related to NPC induction. 4, 5 In fact, the etiological factors have yet to be clearly identified. In previous studies in which we attempted to investigate the molecular mechanism of NPC pathogenesis, we established nine NPC cell lines. 6, 7 Research findings on these cell lines and their original biopsy specimens indicate that EBV plays a major role in promoting tumor progression in NPC pathogenesis. [8] [9] [10] [11] [12] In one of our experiments, 12 we used severe combined immunodeficiency (SCID) mice to produce EBV þ and EBV À xenografts, in which certain oncogenes such as EGFR were only expressed in a fraction of EBV À tumor cells; EBV infection could enhance those cells to express the EGFR gene, but could not turn on the EGFR gene in other tumor cells which did not express this gene. 12 However, this finding was a morphological observation. In order to dissect the molecular mechanism for this phenomenon, in the present study we used a cotransfection system to transfect the EBV-LMP1 gene, p53 gene and mdm2 promoter into p53 mutated NPC cells to observe the actual relationship between EBV and mdm2 gene expression, and also we compared the function of EBV-LAMP1 and EBV-LAMP2A genes in relation to mdm2 gene expression.
In another study, we had investigated the p53 gene and its protein expression in our NPC cell lines. 13 In that study we found a heterozygous point mutation at codon 280 in one of the NPC cell lines (NPC-TW06) similar to the reports from other laboratories. 14, 15 This cell line was used for cotransfection experiment. mdm2 has been identified as an oncogene in the transgenic animal. It is the target gene of p53 protein. Its protein has been shown to negatively regulate p53 function in other cellular systems. [16] [17] [18] [19] For these reasons, we also wanted to find out whether mdm2 expression in NPC cell lines and biopsy specimens could be regulated by EBV infection in vitro and in vivo.
Materials and methods

Cell Lines and Culture
In these experiments, we used three representative NPC cell lines established in our laboratory (NPC-TW01, 04 and 06), one derived from a keratinizing squamous cell carcinoma (NPC-TW01) 14 and the other two (NPC-TW04 and 06) 7 from undifferentiated carcinoma. Although the lines contained EBV DNA at early passages, they became negative after 30 passages. 9 The cell lines we used had undergone 50 passages and showed no EBV signal. They were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 5% fetal calf serum (FCS) and incubated in a 10% CO 2 incubator. The other cell line, B95-8 line, a marmoset lymphoblastoid line containing latent EBV was used to isolate EBV particles and grown in RPMI-1640. This line was obtained from American Type Culture Collection.
Preparation of NPC Biopsy Specimens
A total of 20 NPC biopsy specimens were collected. One part of each specimen was fixed in formaldehyde for routine histopathalogical examination. The other part was directly put into a liquid nitrogen container for extraction of total RNA. In total, 15 of the specimens were identified as WHO type IIB (undifferentiated carcinoma), two as type I (keratinizing squamous cell carcinoma), and one as Type IIA (nonkeratinizing carcinoma).
Preparation of EBV Particles for EBV Infection to NPC Cells
The procedures used to isolate EBV particles and identify viral DNA in the isolated solution were performed in exactly the same way as in a recent report. 12 EBV infection was performed also according to the recent publication 11, 12, 20 using IgA receptor (secretory component protein)-mediated endocytosis. After being infected, the cells were cultured for 10 days, collected and used for the detection of EBV genome by in situ PCR hybridization and EBNA-1 immunostaining, 12 and subjected to the following experiments. To analyze the change of mdm2 gene expression after NPC cells were infected with EBV and in 20 NPC biopsy specimens, we used a semi-quantitative RT-PCR to observe mdm2 mRNA expression as previously descripted. 10 The primer sequences for the mdm2 probe were adapted from a paper by Sigalas et al. 19 They were L (sense) GCA GGG GAG AGT GAT ACA GAT and R (antisense) GAT GGC TGA GAA TAG TCT TCA containing 348 bp in between two primers. For internal control, the actin primer sequences were used as published previously. Wild-type (wt) and mutant-type (mt) p53 genes were cloned and subcloned into pGEM3 from the NPC-TW06 cell line as described previously. 5 Both genes were then transfected by lipofectamine separately into the NPC-TW01 cell line. They were transient transfected lines with a transfection efficiency of about 60%, similar to that reported in one of our previous studies. 13 The tumor cells from EBV À and EBV þ NPC cells and from the wt and mt p53 transfected cells were then subjected to total protein extraction for Western blot analysis of MDM2 expression. 12 We used a-tubulin as an internal control. The data were further analyzed by the densitometry.
Immunolocalization of MDM2 in EBV
Animal Model Bearing EBV þ and EBV À NPC Tumor Masses
The EBV þ and EBV À xenografts produced in SCID mice were obtained from the same animal experiments published in a recent paper 12 in which the SCID mice bearing EBV þ xenograft grew faster and larger than SCID mice bearing EBV À xenograft. Some of the xenograft tissue fragments were fixed in formaldehyde and embedded in paraffin blocks for double localization of MDM2 and EBER-1 using the same technique described in the published paper.
Transient Cotransfection and Conditioned Media
The transfection of different plasmids into NPC-TW06 cells (with heterozygous mutation of p53 at codon 280) and NPC-TW04 cells (with wt p53) separately was carried out in the 6 cm-diameter Petri dish containing 5 Â 10 5 cells per dish with the use of Lipofectamine 2000 (Invitrogen) following the manufacturer's protocol. 13, 21 Each cell line was transfected with 3.8 mg of appropriate reporter and effecter plasmids (including pGL2-mdm2-Luc, pGL3-SV40-p53 expression vector, pGL3-CMV-bgal, and pcDNA3.1-CMV-LMP1 and pRc/CMV-LMP2A. NPC cells for the transfection experiment were cultured in DMEM with 10% fetal calf serum before the transfection was performed. During transfection, the cells were cultured in a serum-free medium (OPTI-MEM, GIBCO/BRL) without antibiotics for 4 h at 371C. After 2 days, the transfected cells were collected for luciferase assay. Transfection efficiency was normalized by cotransfection with a b-galactosidase reporter construct. The luciferase and galactosidase assays were performed according to the instructions in the commercial kits (Promega, MI, USA). Each transfection experiment was repeated four times.
Colocalization of MDM2 and EBER-1, p53 and EBER-1, MDM2 and p53 in NPC Biopsy Specimens
To colocalize MDM-2 or p53 with EBER-1 in paraffin sections 12, 13 immunostaining was first performed using either monoclonal antibody against MDM2 or rabbit polyclonal antibodies against p53 (prepared by our laboratory as described previously), 13 and then followed by in situ nucleic acid hybridization of EBV with EBER-1 antisense probe, 9,12 respectively. The substrate for immunostaining was peroxidase substrate, and the substrate for in situ hybridization was alkaline phosphatase (AP) substrate. In the double localization of MDM2 and p53, we used monoclonal antibodies against MDM2 plus AP-labeled second antibodies, and rabbit polyclonal antibodies against p53 plus peroxidase-labeled second antibodies. We used a sense probe to replace an antisense probe as an EBER-1 negative control, 9 and used normal mouse serum and normal rabbit serum as the primary antibodies for negative immunostaining. No specific EBV signal could be detected when a sense probe was used, nor was immunostaining seen in the control normal serumtreated cells.
Results
Localization of MDM2 Protein in EBV
À and EBV þ
NPC-TW01 Cells
When NPC-TW01 cells were infected by EBV and in situ PCR hybridization and immunohistochemical localization using antibodies against EBNA-1 were performed, the infection efficiency was about 90% (data not shown). When EBV À NPC-TW01 cells were stained with mAb against MDM2, a small subset of individual tumor cells showed weak to moderate and a few cells revealed strong anti-MDM2 immunostaining ( Figure EBV to observe MDM2 expression, but we did perform an experiment using the cotransfection of a plasmid containing wt p53 and another plasmid containing pLMP1 to NPC cells (as described in the following section).
Identification of LMP1 Enhancement of p53 Activity to Activate the mdm2 Promoter by Cotransfection Experiments
Analysis of the activity of the mdm2 promoter in 
Localization of MDM2 and p53 Protein in NPC Biopsy Specimens
When 20 NPC paraffin sections were stained with antibodies against MDM2, one section was unreadable due to poor fixation and three showed no MDM2 immunostaining. The other 16 revealed sporadic tumor cells containing reaction product of anti-MDM2 in the nuclei. The distribution of positive cells was random and most tumor cells were unstained (Figure 7a) . When stained by polyclonal anti-p53 antibodies, only a few cells in most NPC biopsy specimens showed nuclear staining, a few revealed more p53 stained cells than others (data not shown). 
Colocalization of MDM2 and EBER-1 in Biopsy Specimens
In each of the 19 biopsy specimens, EBV þ NPC cells (Figure 7b , short arrows, blue stained cells) were randomly distributed in the tumor and intermingled with EBV À and MDM2 À tumor cells (Figure 7b , small arrowhead), similar to previously described findings. 9, 11 In 16 cases, different degrees of nuclear staining of anti-MDM2 reaction product (brown) was seen in some EBV À cells (Figure 7b , large arrowhead, brown color) and in some EBV þ cells (Figure 7b, long (Table  1) .When EBER-1 sense probe to replace the antisense probe was used to detect EBV in the sections, no specific EBV signal was seen (data not shown). When in situ PCR hybridization was used to detect EBV-DNA in the biopsy specimens, the result was the same as that of in situ hybridization of EBER-1 (data not shown), a result similar to our recent report. 12 
Colocalization of p53 and EBER-1 in NPC Biopsy Specimens
Five out of the 18 readable specimens showed no p53 staining. The others revealed sporadic p53 þ with EBER-1 þ 16% ( Table 2) .
Colocalization of MDM2 and p53 in Biopsy Specimens
We selected four biopsy specimens to perform double localization of MDM2 and p53. The antip53 reaction product was brown, while the anti-MDM2 reaction product was blue. We found certain tumor cells to be stained with both strong MDM2 and p53 reaction products (Figure 7d , large white arrowheads, brownish black). Only very rarely if at all did a tumor cell show p53 staining only, though some other tumor cells did show MDM2 reaction product only (Figure 7d , long arrows, blue color). Many tumor cells did not show either MDM2 or p53 staining (Figure 7d , small arrowhead). Some small cells, which might be tumor-infiltrating lymphocytes (short arrow), did not contain EBV signal. The average number of MDM2 þ plus p53 þ in the four selected cases was 29%.
Discussion
In the present study, results from immunostaining, RT-PCR and Western blotting from EBV-infected cells all indicate that EBV can enhance mdm2 expression in a subset of cells that express this gene in vitro. This result is different from a previous report, 18 in which no relationship was found between the presence of EBV and the expression of MDM2 protein in B lymphocytes. In order to determine whether these results would also be the same in vivo, we used SCID mice bearing EBV þ and EBV À NPC-TW01 xenografts published in a recent paper. 12 The findings that both EBV þ and EBV À xenografts containing clusters of tumor cells with MDM2 protein expression were surrounded by MDM2 À tumor cells (Figure 3 ) indicate that the MDM2 expressed NPC cells proliferate faster than the MDM2-negative cells and suggest that mdm2 gene has an oncogene like function. 16, 18, 22 This finding was also supported by our in vitro cultured EBV þ NPC cells, which showed stronger MDM2 expression cells grown in clusters (Figure 1 ). The fact that MDM2 expression was stronger in the EBV þ mass than in the EBV À mass also indicates that EBV can enhance the MDM2 expression in the tumor cells that express this gene. Thus, the enhanced MDM2 expression in a subset of NPC cells after EBV infection may also play a role for EBV to promote tumor cell proliferation, as has been suggested previously. 23, 24 Since many EBV þ and EBV À cells in mouse tumor masses also showed no MDM2 expression (Figure 3 ), EBV may not be able to turn on the mdm2 gene expression in tumor cells that do not express MDM2 protein. In other words, EBV may only indirectly enhance MDM2 expression in tumor cells that express this protein but cannot turn on mdm2 genes in cells that do not express this gene. This phenomenon seems to suggest that instead of EBV being a promoter able to turn on certain oncogenes or cell cycle regulatory factors to express their proteins in B lymphocytes in order to drive the G 0 phase cells getting into the cell cycle, 3, 24 it may be an enhancer only able to enhance the gene expression in the epithelial tumor cells that have already expressed this protein.
LMP1 has even been proposed in one report that in NPC it may contribute to invasiveness and metastasis through the induction of MMP-9 transcription and enzymatic activity. 25 Since the authors in that report used a uterine cervical cancer cell line, which could express an MMP-9 transcript, it does not explain why EBV cannot induce MDM2 gene expression in the cells that do not express this gene, as shown in Figure 3a . In order to clarify this discrepancy, we used NPC-TW06 cell line, which has a heterozygous point mutation of p53 as mentioned above for our cotransfection experiment ( Figure 5 ). Our results showed that LMP1 alone could not induce mdm2 promoter to express luciferase activity, yet the p53 protein could. In addition, LMP1 could enhance p53 activity to upregulate mdm2 promoter. This conclusion was also confirmed by the other cotransfection experiment that in the NPC cell line containing wt p53 gene, only pcDNA3.1-CMV-LMP1 and pGL2-mdm2-Luc without exogenous p53 gene could upregulate mdm2-Luc activity (Figure 5b, lane 4) . These findings support our hypothesis that EBV (LMP1) can indirectly enhance certain gene expressions in NPC cells that express those genes, but cannot induce gene expressions in cells that do not express them. In addition, another cotransfection experiment also indicates that it is EBV-LMP1 but not EBV-LMP2A gene can indirectly regulate expressed mdm2 gene (Figure 5c ). In one of our unpublished data, we have also transfected EBNA-1 gene to EBV þ NPC cells and showed no specific function of EBNA-1 gene to alter host gene expression, similar to LMP-2A.
The findings that 16 out of 20 NPC cases contained weak to moderate mdm2 expression, suggest that the expression of mdm2 gene in different NPC tissue fragments is variable. The result that about 80% of NPC biopsy specimens have more or less expressed mdm2 mRNA is different from a previous report that mdm2 gene was infrequently amplified or expressed in NPC. 26 That only about 35% of tumor cells expressed MDM2 protein in each case (Table 1) suggests that overexpression of MDM2 protein in those tumor cells may occur during NPC tumor progression. Apparently, the mdm2 gene is not a 'gate keeper' gene for nasopharyngeal carcinoma. In addition, since certain MDM2-positive tumor cells were not infected by EBV (Figure 7 ), indicating that in vivo in NPC biopsy specimen mdm2 gene expression in certain tumor cells is independent from EBV infection.
The fact that some tumor cells did contain both MDM2 protein and EBV signal suggests that EBV may enhance mdm2 gene expression in these cells, a finding similar to the above-mentioned animal model. Our double localization of p53 and EBV in NPC biopsy specimens also demonstrated that some p53-containing cells may or may not be infected by EBV (Figure 7c ), indicating that p53 expression in NPC biopsy specimen is also independent of EBV infection. But in the EBV þ -p53 þ cells, the p53 gene expression can be enhanced by EBV infection (Figure 5a, lane 4) . mdm2 gene can be upregulated by p53 protein; it can also be regulated by the Ras-driven Raf/MEK/ MAP kinase pathway in a p53-independent manner. 27, 28 Whether this is also true in NPC is not clear. In the double localization of MDM2 and p53 in NPC biopsy specimens, only a fraction of MDM2-positive tumor cells contained p53 protein but most or all p53-positive cells contained MDM2 protein. This finding combined with the result from the wt p53 transfection experiment, which showed upregulation of mdm2 gene expression, suggests that in wt p53-positive NPC tumor cells, p53 protein can up regulate MDM2 expression, but in MDM2-positive and p53-negative cells MDM2 expression is independent from p53 protein regulation. This finding supports the recent report that mdm2 may be regulated by other signal pathways as mentioned above. The presence of MDM2 in those NPC tumor cells with negative p53 protein indicates that some functions of MDM2 are independent from p53 interaction, and may also have a role in promoting tumor growth [23] [24] [25] and increasing anchorage-independent growth 29 in the pathogenesis of NPC. This conclusion is somewhat different from one previous study that has reported that mdm2 may deregulate the p53-dependent growth suppressive pathway in the pathogenesis of NPC. 29 It is concluded that EBV plays a major role as an enhancer to the progression of NPC tumorigenicity and that EBV can enhance the expression of endogenous p53 and indirectly upregulate mdm2 expression only in the tumor cells that express MDM2 protein, but cannot turn on mdm2 gene in cells that do not express this protein. In other words, EBV can indirectly enhance MDM2 expression through enhancement of p53 activation in a subset of NPC cells to promote EBV þ tumor growth.
